Immunosuppressants drugs - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.84 [0.62, 1.14]< 122%10 studies (10/-)87.0 %some concernlow moderatecrucial-
deaths 0.79 [0.64, 0.99]< 123%17 studies (17/-)98.1 %some concernlow moderatecrucial-
deaths (time to event analysis only) 1.04 [0.78, 1.38]< 10%3 studies (3/-)39.8 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.56 [0.26, 1.20]< 10%1 study (1/-)93.1 %NAnot evaluable important-
clinical improvement 1.43 [1.13, 1.82]> 136%7 studies (7/-)99.8 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.89 [1.30, 2.74]> 10%2 studies (2/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.33 [0.95, 1.87]> 10%4 studies (4/-)95.3 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.09 [0.87, 1.35]> 10%2 studies (2/-)76.9 %some concernnot evaluable moderateimportant-
death or ventilation 0.96 [0.65, 1.43]< 126%3 studies (3/-)57.8 %some concernnot evaluable moderateimportant-
hospital discharge 0.97 [0.79, 1.20]> 10%1 study (1/-)38.9 %NAnot evaluable important-
mechanical ventilation 0.62 [0.16, 2.31]< 151%4 studies (4/-)76.3 %some concernnot evaluable moderateimportant-
ICU admission 1.04 [0.17, 6.33]< 175%2 studies (2/-)48.5 %some concernnot evaluable moderatenon important-
recovery 1.30 [0.64, 2.66]> 19%2 studies (2/-)76.5 %lownot evaluable highnon important-

safety endpoints 00

related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
serious adverse events 0.99 [0.77, 1.28]< 116%6 studies (6/-)52.7 %some concernserious moderateimportant-
adverse events 1.14 [0.87, 1.50]< 122%7 studies (7/-)16.7 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.